表紙
市場調査レポート

ラクオリア創薬 : 製品パイプライン分析

RaQualia Pharma Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 203738
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
ラクオリア創薬 : 製品パイプライン分析 RaQualia Pharma Inc. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 42 Pages
概要

ラクオリア創薬 は東京に拠点を置く、臨床および前臨床候補の薬剤を創薬・開発・商品化し、世界的に展開している製薬会社です。製品には胃不全麻痺、慢性便秘、神経因性疼痛、癌に伴う食欲不振、慢性炎症性疼痛、急性痛、アレルギー、アルツハイマー病などの治療薬があります。

当レポートでは、ラクオリア創薬における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを提供しています。

ラクオリア創薬の基本情報

ラクオリア創薬の概要

  • 主要情報
  • 企業情報

ラクオリア創薬:R&Dの概要

  • 主な治療範囲

ラクオリア創薬:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

ラクオリア創薬:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

ラクオリア創薬:薬剤プロファイル

  • RQ-00000004
  • RQ-00000010
  • RQ-00000774
  • RQ-00201894
  • RQ-00202730
  • RQ-00203066
  • RQ-00310941
  • RQ-00432933
  • 神経因性疼痛向け Cav3.2 阻害薬
  • 疼痛向け Nav1.7 ナトリウム・チャネル阻害薬
  • 疼痛向け Nav1.8 ナトリウム・チャネル阻害薬
  • 神経因性疼痛向け TRPM8 阻害薬
  • 未公表の症状向け特殊イオン・チャネル調整薬
  • 疼痛向け特殊イオン・チャネル調整薬

ラクオリア創薬:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

ラクオリア創薬:最近のパイプライン動向

ラクオリア創薬:休止中のプロジェクト

ラクオリア創薬:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07409CDB

Summary

Global Markets Direct's, 'RaQualia Pharma Inc. - Product Pipeline Review - 2015', provides an overview of the RaQualia Pharma Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RaQualia Pharma Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of RaQualia Pharma Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of RaQualia Pharma Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the RaQualia Pharma Inc.'s pipeline products

Reasons to buy

  • Evaluate RaQualia Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of RaQualia Pharma Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the RaQualia Pharma Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of RaQualia Pharma Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of RaQualia Pharma Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of RaQualia Pharma Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • RaQualia Pharma Inc. Snapshot
    • RaQualia Pharma Inc. Overview
    • Key Information
    • Key Facts
  • RaQualia Pharma Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • RaQualia Pharma Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • RaQualia Pharma Inc. - Pipeline Products Glance
    • RaQualia Pharma Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • RaQualia Pharma Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • RaQualia Pharma Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • RaQualia Pharma Inc. - Drug Profiles
    • RQ-00000004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00000010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00000774
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00201894
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00202730
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00203066
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00310941
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00432933
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block Cav3.2 for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Nav1.7 Sodium Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Nav1.8 Sodium Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block TRPM8 for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Modulate Specific Ion Channel for an Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Modulate Specific Ion Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • RaQualia Pharma Inc. - Pipeline Analysis
    • RaQualia Pharma Inc. - Pipeline Products by Target
    • RaQualia Pharma Inc. - Pipeline Products by Route of Administration
    • RaQualia Pharma Inc. - Pipeline Products by Molecule Type
    • RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action
  • RaQualia Pharma Inc. - Recent Pipeline Updates
  • RaQualia Pharma Inc. - Dormant Projects
  • RaQualia Pharma Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • RaQualia Pharma Inc., Key Information
  • RaQualia Pharma Inc., Key Facts
  • RaQualia Pharma Inc. - Pipeline by Indication, 2015
  • RaQualia Pharma Inc. - Pipeline by Stage of Development, 2015
  • RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2015
  • RaQualia Pharma Inc. - Out-Licensed Products in Pipeline, 2015
  • RaQualia Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • RaQualia Pharma Inc. - Phase III, 2015
  • RaQualia Pharma Inc. - Phase I, 2015
  • RaQualia Pharma Inc. - Preclinical, 2015
  • RaQualia Pharma Inc. - Discovery, 2015
  • RaQualia Pharma Inc. - Pipeline by Target, 2015
  • RaQualia Pharma Inc. - Pipeline by Route of Administration, 2015
  • RaQualia Pharma Inc. - Pipeline by Molecule Type, 2015
  • RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action, 2015
  • RaQualia Pharma Inc. - Recent Pipeline Updates, 2015
  • RaQualia Pharma Inc. - Dormant Developmental Projects,2015
  • RaQualia Pharma Inc., Other Locations
  • RaQualia Pharma Inc., Subsidiaries

List of Figures

  • RaQualia Pharma Inc. - Pipeline by Top 10 Indication, 2015
  • RaQualia Pharma Inc. - Pipeline by Stage of Development, 2015
  • RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2015
  • RaQualia Pharma Inc. - Pipeline by Top 10 Target, 2015
  • RaQualia Pharma Inc. - Pipeline by Top 10 Route of Administration, 2015
  • RaQualia Pharma Inc. - Pipeline by Top 10 Molecule Type, 2015
  • RaQualia Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top